Literature DB >> 6406470

Clinical pharmacokinetics of bupropion: a review.

A A Lai, D H Schroeder.   

Abstract

Bupropion is absorbed rapidly after single-dose oral administration of tablets, capsules, or aqueous solution of the hydrochloride salt. Peak bupropion plasma concentrations are generally attained within 2 hours, followed by a biphasic decline. The half-life of the initial (alpha) phase is approximately 1.5 hours and that of the second (beta) phase is approximately 14.0 hours. An oral dose of bupropion is subjected to extensive first-pass metabolism. The ratio between plasma clearance and fraction absorbed (approximately 2 L/hr/kg) is consistent within the 50-250 mg single dose range.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6406470

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  A case report of seizure induced by bupropion nasal insufflation.

Authors:  Stanley Hill; Harminder Sikand; Jonathan Lee
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Metabolism of bupropion by baboon hepatic and placental microsomes.

Authors:  Xiaoming Wang; Doaa R Abdelrahman; Valentina M Fokina; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Biochem Pharmacol       Date:  2011-05-05       Impact factor: 5.858

4.  The effect of bupropion, a new antidepressant drug, and alcohol and their interaction in man.

Authors:  M J Hamilton; M S Bush; A W Peck
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.

Authors:  Andy Z X Zhu; Qian Zhou; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-09-03       Impact factor: 3.922

6.  CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.

Authors:  A Z X Zhu; L S Cox; N Nollen; B Faseru; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2012-11-14       Impact factor: 6.875

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity.

Authors:  M Bourin; M C Colombel; M Malinge; J Bradwejn
Journal:  J Psychiatry Neurosci       Date:  1991-11       Impact factor: 6.186

9.  Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach.

Authors:  Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Raghotham Reddy Pinninti; Jianhong Chen; Peter A Crooks; Audra L Stinchcomb
Journal:  J Pharm Sci       Date:  2009-02       Impact factor: 3.534

10.  Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.

Authors:  Rebecka Coles; Evan D Kharasch
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.